SOURCE: Gene Express, Inc.

March 17, 2008 09:29 ET

Gene Express Appoints James L. Mulshine, M.D. to Its Scientific Advisory Board

TOLEDO, OH--(Marketwire - March 17, 2008) - Gene Express, Inc. today announced that it has appointed James L. Mulshine, M.D. to its Scientific Advisory Board. Dr. Mulshine will be joining David Johnston, Ph.D., Dr. David Sidransky, M.D. and Michael N. Liebman, Ph.D., as previously announced on December 19 and November 29, further adding to this esteemed group of internationally recognized experts.

Gerald Vardzel, CEO of Gene Express, commented, "We are honored to have Dr. Mulshine join our Scientific Advisory Board. His research focused on biomarkers of lung cancer, and his groundbreaking work in developing innovative technological approaches to cellular diagnostics, fall perfectly in line with Gene Express' strategy to accelerate drug and molecular diagnostic development to enable the development of targeted therapies for specific disease processes, while enhancing safety and providing a standard measurement system."

James L. Mulshine M. D., noted oncologist at the National Cancer Institute (NCI) for twenty-five years, is now the Associate Provost for Research at Rush University Medical Center in Chicago. He was previously Head of the Intervention Section, Cell and Cancer Biology Department, Division of Clinical Sciences for the NCI in Maryland. After graduating from the Loyola Stritch School of Medicine in 1977, he completed a Fellowship in Internal Medicine and was a Medical Resident at the Cleveland Clinic Foundation. He completed his training in medical oncology and spent a total of nine years in the NCI - Navy Medical Oncology Branch. In 1990, he moved to the Division of Cancer Prevention and Control to start an Intramural Translation Research Group that was moved back to the Division of Clinical Sciences in 1996.

Dr. Mulshine is a Fellow in the American College of Physicians, as well as a member of the American Society of Clinical Oncology, American Association of Cancer Research, International Association for the Study of Lung Cancer, and the American Federation of Clinical Research. His numerous honors include the NCI Technology Transfer Award (1996), and the National Institute of Health Director's Award in 1998.

His interest in lung cancer research emerged from an opportunity to join the lung cancer biology group of Dr. John Minna in the early eighties. The group at the NCI-Navy included a number of talented investigators that established a footprint for translational research for lung cancer. During a decade of work with the development of new approaches to control advanced lung cancer, Dr. Mulshine evolved into a committed prevention researcher. Much of his current research centers on the chemoprevention, biomarkers, and early detection of lung cancer. He has been a pioneer in developing new technological approaches to cellular diagnostics for early lung cancer detection, as well as drug delivery to address the airway-confined phase of early lung cancer. His focus has been to develop robust, cost effective integrated approaches to the comprehensive management of pre-invasive lung cancer in a population-based setting.

Dr. Mulshine stated, "It is a vibrant time for scientific and technological innovation in developing molecular diagnostics. The team at Gene Express embraces those innovations but understands that the demands of assay validation and tailored regulatory strategy are just as vital to ultimate success in bringing new tools into meaningful clinical application."

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information